Literature DB >> 25467055

L-Ornithine Schiff base-copper and -cadmium complexes as new proteasome inhibitors and apoptosis inducers in human cancer cells.

Zhongyu Zhang1, Caifeng Bi, Yuhua Fan, Nan Zhang, Rahul Deshmukh, Xingchen Yan, Xiuwen Lv, Pengfei Zhang, Xia Zhang, Q Ping Dou.   

Abstract

Ubiquitin-proteasome system (UPS) plays a crucial role in many cellular processes such as cell cycle, proliferation and apoptosis. Aberrant activation of UPS may result in cellular transformation or other altered pathological conditions. Previous studies have shown that metal-based complexes could inhibit proteasome activity and induce apoptosis in certain human cancer cells. In the current study, we report that the cadmium and copper complexes with heterocycle-ornithine Schiff base are potent inhibitors of proteasomal chymotrypsin-like (CT-like) activity, leading to induction of apoptosis in cancer cells. Two novel copper-containing complexes and two novel cadmium-containing complexes with different heterocycle-ornithine Schiff base structures as ligands were synthesized and characterized. We found that complexes Cu1, Cd1 and Cd2 show proteasome-inhibitory activities in human breast cancer MDA-MB-231 and human prostate cancer LNCaP cells, resulting in the accumulation of p27, a natural proteasome substrate and other ubiquitinated proteins, followed by the induction of apoptosis. Our results suggest that metal complexes with heterocycle-ornithine Schiff base have proteasome-inhibitory capabilities and have the potential to be developed into novel anticancer drugs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25467055     DOI: 10.1007/s00775-014-1219-1

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  32 in total

1.  Ubiquitin-proteasome system, a new anti-tumor target.

Authors:  Wei Du; Qi-bing Mei
Journal:  Acta Pharmacol Sin       Date:  2013-02       Impact factor: 6.150

2.  Proteasome from Thermoplasma acidophilum: a threonine protease.

Authors:  E Seemüller; A Lupas; D Stock; J Löwe; R Huber; W Baumeister
Journal:  Science       Date:  1995-04-28       Impact factor: 47.728

Review 3.  Cellular processing of platinum anticancer drugs.

Authors:  Dong Wang; Stephen J Lippard
Journal:  Nat Rev Drug Discov       Date:  2005-04       Impact factor: 84.694

Review 4.  From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).

Authors:  Christian G Hartinger; Stefanie Zorbas-Seifried; Michael A Jakupec; Bernd Kynast; Haralabos Zorbas; Bernhard K Keppler
Journal:  J Inorg Biochem       Date:  2006-02-28       Impact factor: 4.155

5.  Novel Schiff base copper complexes of quinoline-2 carboxaldehyde as proteasome inhibitors in human prostate cancer cells.

Authors:  Shreelekha Adsule; Vivek Barve; Di Chen; Fakhara Ahmed; Q Ping Dou; Subhash Padhye; Fazlul H Sarkar
Journal:  J Med Chem       Date:  2006-11-30       Impact factor: 7.446

6.  Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.

Authors:  Muthu Selvakumaran; Debra A Pisarcik; Rudi Bao; Anthony T Yeung; Thomas C Hamilton
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

7.  Organic cadmium complexes as proteasome inhibitors and apoptosis inducers in human breast cancer cells.

Authors:  Zhen Zhang; Caifeng Bi; Daniela Buac; Yuhua Fan; Xia Zhang; Jian Zuo; Pengfei Zhang; Nan Zhang; Lili Dong; Q Ping Dou
Journal:  J Inorg Biochem       Date:  2013-02-21       Impact factor: 4.155

8.  Disulfiram promotes the conversion of carcinogenic cadmium to a proteasome inhibitor with pro-apoptotic activity in human cancer cells.

Authors:  Lihua Li; Huanjie Yang; Di Chen; Cindy Cui; Q Ping Dou
Journal:  Toxicol Appl Pharmacol       Date:  2008-02-05       Impact factor: 4.219

Review 9.  From bortezomib to other inhibitors of the proteasome and beyond.

Authors:  Daniela Buac; Min Shen; Sara Schmitt; Fathima Rani Kona; Rahul Deshmukh; Zhen Zhang; Christine Neslund-Dudas; Bharati Mitra; Q Ping Dou
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

10.  Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells.

Authors:  Kenyon G Daniel; Di Chen; Shirley Orlu; Qiuzhi Cindy Cui; Fred R Miller; Q Ping Dou
Journal:  Breast Cancer Res       Date:  2005-09-20       Impact factor: 6.466

View more
  2 in total

1.  Design, synthesis, molecular modeling, and bioactivity evaluation of 1,10-phenanthroline and prodigiosin (Ps) derivatives and their Copper(I) complexes against mTOR and HDAC enzymes as highly potent and effective new anticancer therapeutic drugs.

Authors:  M Mustafa Cetin; Wenjing Peng; Daniel Unruh; Michael F Mayer; Yehia Mechref; Kemal Yelekci
Journal:  Front Pharmacol       Date:  2022-10-04       Impact factor: 5.988

2.  The protease DDI2 regulates NRF1 activation in response to cadmium toxicity.

Authors:  Sérgio T Ribeiro; Aude de Gassart; Sarah Bettigole; Lea Zaffalon; Claire Chavarria; Melanie Op; Kalvin Nugraha; Fabio Martinon
Journal:  iScience       Date:  2022-09-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.